Get Premium to unlock powerful stock data
Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

$ 48.43 +1.49 (+3.17%) 03:15 PM EST
P/E:
At Loss
P/B:
3.77
Market Cap:
$ 3.70B
Enterprise V:
$ 2.78B
Volume:
618.46K
Avg Vol (2M):
1.03M
Also Trade In:
Volume:
618.46K
Market Cap $:
3.70B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.03M
Enterprise Value $:
2.78B
PB Ratio:
3.77
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for NTLA (Intellia Therapeutics Inc) from 2016 to May 19 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Intellia Therapeutics stock (NTLA) PE ratio as of May 19 2022 is 0. More Details

Intellia Therapeutics PE Ratio (TTM) Chart

EMBED

Intellia Therapeutics PE Ratio (TTM) Historical Data

Total 1241
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Intellia Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-05-19At Loss 2022-03-17At Loss
2022-05-18At Loss 2022-03-16At Loss
2022-05-17At Loss 2022-03-15At Loss
2022-05-16At Loss 2022-03-14At Loss
2022-05-13At Loss 2022-03-11At Loss
2022-05-12At Loss 2022-03-10At Loss
2022-05-11At Loss 2022-03-09At Loss
2022-05-10At Loss 2022-03-08At Loss
2022-05-09At Loss 2022-03-07At Loss
2022-05-06At Loss 2022-03-04At Loss
2022-05-05At Loss 2022-03-03At Loss
2022-05-04At Loss 2022-03-02At Loss
2022-05-03At Loss 2022-03-01At Loss
2022-05-02At Loss 2022-02-28At Loss
2022-04-29At Loss 2022-02-25At Loss
2022-04-28At Loss 2022-02-24At Loss
2022-04-27At Loss 2022-02-23At Loss
2022-04-26At Loss 2022-02-22At Loss
2022-04-25At Loss 2022-02-21At Loss
2022-04-22At Loss 2022-02-18At Loss
2022-04-21At Loss 2022-02-17At Loss
2022-04-20At Loss 2022-02-16At Loss
2022-04-19At Loss 2022-02-15At Loss
2022-04-18At Loss 2022-02-14At Loss
2022-04-15At Loss 2022-02-11At Loss
2022-04-14At Loss 2022-02-10At Loss
2022-04-13At Loss 2022-02-09At Loss
2022-04-12At Loss 2022-02-08At Loss
2022-04-11At Loss 2022-02-07At Loss
2022-04-08At Loss 2022-02-04At Loss
2022-04-07At Loss 2022-02-03At Loss
2022-04-06At Loss 2022-02-02At Loss
2022-04-05At Loss 2022-02-01At Loss
2022-04-04At Loss 2022-01-31At Loss
2022-04-01At Loss 2022-01-28At Loss
2022-03-31At Loss 2022-01-27At Loss
2022-03-30At Loss 2022-01-26At Loss
2022-03-29At Loss 2022-01-25At Loss
2022-03-28At Loss 2022-01-24At Loss
2022-03-25At Loss 2022-01-21At Loss
2022-03-24At Loss 2022-01-20At Loss
2022-03-23At Loss 2022-01-19At Loss
2022-03-22At Loss 2022-01-18At Loss
2022-03-21At Loss 2022-01-17At Loss
2022-03-18At Loss 2022-01-14At Loss

Intellia Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Intellia Therapeutics Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325413 SIC : 2835
Traded in other countries / regions
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.